FREELINE THERAPEUTICS HLDGS's ticker is FRLN and the CUSIP is 35655L107. A total of 1 filers reported holding FREELINE THERAPEUTICS HLDGS in Q3 2023. The put-call ratio across all filers is - and the average weighting 9.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $19,569 | -5.5% | 43,005 | -1.4% | 0.00% | – |
| Q4 2022 | $20,717 | -42.5% | 43,605 | -14.3% | 0.00% | – |
| Q3 2022 | $36,000 | -39.0% | 50,905 | -25.2% | 0.00% | – |
| Q2 2022 | $59,000 | -60.4% | 68,041 | -48.8% | 0.00% | – |
| Q1 2022 | $149,000 | +84.0% | 132,822 | +223.4% | 0.00% | – |
| Q4 2021 | $81,000 | -72.4% | 41,073 | -52.2% | 0.00% | -100.0% |
| Q3 2021 | $293,000 | – | 85,959 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,466,507 | $6,217,990 | 9.26% |